Skip to main content Help with accessibility Skip to main navigation

UPADACITINIB prolonged-release tablets (RINVOQ ®▼) for Crohn's disease

CCG Approval Status:

Ha
Kn
Li
SF
SS
SH
Wa
WL
Wi
Date Added: 23 - Mar - 2023
Body System:
Grey
UPADACITINIB prolonged-release tablets (RINVOQ ®▼) for Crohn's disease

The Cheshire and Merseyside Interim Area Prescribing Group does not currently recommend the prescribing of UPADACITINIB prolonged-release tablets (RINVOQ ®▼) for Crohn's disease.